Increased angiogenesis is important in the pathophysiology of solid tumors. Recent studies show that angiogenesis and angiogenic factors play an important role in hematological malignancies. Both acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are associated with a substantial increase in vascularity in the bone marrow as well as increased levels of various angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, angiogenin, angiopoietin-1, platelet-derived growth factor, hepatocyte growth factor, epidermal growth factor, tumor necrosis factor-α, and transforming growth factor-α and transforming growth factor-β. Most of these angiogenic factors appear to be secreted by the neoplastic hematopoietic cells and appear to promote the growth and proliferation of the leukemic cells in an autocrine fashion. More importantly, angiogenic factors play a role in the clinical behavior and outcome of both AML and MDS. Despite significant overlap between MDS and AML in many aspects, higher levels of cellular VEGF and lower levels KDR are seen in MDS than in AML. Antiangiogenic therapy may play a role in AML and MDS and some differences in response may exist between MDS and AML.

Keywords:
Angiogenesis, Fibroblast growth factor, basic, Hepatocyte growth factor, Leukemia, Neovascularization, Receptors, Tumor necrosis factor-α, Vascular endothelial growth factor
1.
Fanelli M, Locopo N, Gattuso D, Gasparini G: Assessment of tumor vascularization: Immunohistochemical and non-invasive methods. Int J Biol Markers 1999;14:218–231.
2.
Samejima N, Yamazaki K: A study on the vascular proliferation in tissues around the tumor in breast cancer. Jpn J Surg 1988;18:235–242.
3.
Edel MJ, Robbins PD, Papadimitriou JM, D’Antuono MF, Harvey JM, Mitchel CA, Dawkins HJ: Assessment of vascularity in breast carcinoma by computer-assisted video analysis (CAVA) and its association with axillary lymph node status. Breast Cancer Res Treat 1998;47:17–27.
4.
Piérard GE, Piérard-Franchimont C: Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. Eur J Cancer 1997;33:1888–1892.
5.
Tanigawa N, Matsumura M, Amaya H, Kitaoka A, Shimomatsuya T, Lu C, Muraoka R, Tanaka T: Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997;79:220–225.
6.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating M, Freireich E, Albitar M: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240–2245.
7.
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;50:815–821.
8.
Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637–2644.
9.
Hussong JW, Rodgers GM, Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309–313.
10.
Orkin SH, Porcher C, Fujiwara Y, Visvader J, Wang LC: Intersections between blood cell development and leukemia genes. Cancer Res 1999;59(7 suppl):1784–1788.
11.
Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF: Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000;87:728–730.
12.
Ribatti D, Vacca A, Roncali L, Dammacco F: Hematopoiesis and angiogenesis: A link between two apparently independent processes. J Hematother Stem Cell Res 2000;9:13–19.
13.
Mangi MH, Newland AC: Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000;111:43–51.
14.
Bellamy WT, Richter L, Frutiger Y, Grogan TM: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728–733.
15.
Allouche M: Basic fibroblast growth factor and hematopoiesis. Leukemia 1995;96:937–942.
16.
Allouche M, Bikfalvi A: The role of fibroblast growth factor-2 (FGF-2) in hematopoiesis. Prog Growth Factor Res 1995;6:35–48.
17.
Bikfalvi A, Han ZC: Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 1994;8:523–529.
18.
Gerwins P, Skoldenberg E, Claesson-Welsh L: Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000;34:185–194.
19.
Sensebe L, Deschaseaux M, Li J, Hervé P, Charbord P: The broad spectrum of cytokine gene expression by myoid cells from the human marrow microenvironment. Stem Cells 1997;15:133–143.
20.
Schott RJ, Morrow LA: Growth factors and angiogenesis. Cardiovasc Res 1993;27:1155–1161.
21.
Visvader JE, Fujiwara Y, Orkin SH: Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev 1998;12:47347–47349.
22.
Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F: Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398–1401.
23.
Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K: Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049–2054.
24.
Tobler A, Moser B, Dewald B, Geiser T, Studer H, Baggiolini M, Fey MF: Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 1993;82:2517–2525.
25.
Salven P, Orpana A, Joensuu H: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5:487–491.
26.
Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, Dupriez B: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441–448.
27.
Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI: Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen? Int J Oncol 2000;17:149–152.
28.
Gunsilius E, Gastl G: Platelets and VEGF blood levels in cancer patients. Br J Cancer 1999;81:185–186.
29.
Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA: Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000;80:443–454.
30.
Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E: Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 2000;95:353-357.
31.
Ziegler BL, Valtieri M, Porada GA, De Maria R, Muller R, Masella B, Gabbianelli M, Casella I, Pelosi E, Bock T, Zanjani ED, Peschle C: KDR receptor: A key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.
32.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952–958.
33.
Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511–521.
34.
Borset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A: The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma 1999;32:249–256.
35.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Estey E, Albitar M: Cellular VEGF is an independent predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717–3721.
36.
Albitar M, Estey E, Cortes J, O’Brien S, Giles F, Kurzrock R: Prognostic significance of cytokine levels in newly-diagnosed AML and high-risk myelodysplasia. Submitted.
© 2001 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.